Get the Stockscreener App
335.11
0.37%
-1.375
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $335.11, with a volume of 640.92K.
It is down -0.37% in the last 24 hours and down -0.82% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$336.48
Open:
$336.22
24h Volume:
640.92K
Relative Volume:
0.25
Market Cap:
$180.87B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
23.30
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-1.20%
1M Performance:
-0.82%
6M Performance:
-2.96%
1Y Performance:
+18.23%
1-Day Range:
$333.06
$337.18
1-Week Range:
$333.06
$342.49
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
335.13 | 181.60B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,093.31 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.49 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.18 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.82 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.49 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. $AMGN Shares Acquired by National Pension Service - MarketBeat
Ilmarinen Mutual Pension Insurance Co Has $28.54 Million Position in Amgen Inc. $AMGN - MarketBeat
Intech Investment Management LLC Grows Holdings in Amgen Inc. $AMGN - MarketBeat
17,124 Shares in Amgen Inc. $AMGN Acquired by Fideuram Asset Management Ireland dac - MarketBeat
RTX, Wells Fargo (WFC) And Amgen (AMGN) Face Mixed Outlooks As Analysts Weigh Growth Against Key Risks - foreignpolicyjournal.com
Amgen Inc. stock (US0311621009): Shares steadier as S&P 500 biotech name trades around recent range - AD HOC NEWS
Has Amgen Stock Quietly Become a Value Opportunity? - Trefis
Amgen Inc. stock (US0311621009): Venture arm backs cold-chain specialist Ember LifeSciences - AD HOC NEWS
Amgen Inc. $AMGN Shares Purchased by Smith Chas P & Associates PA Cpas - MarketBeat
Amgen Inc. $AMGN Stake Boosted by Integrity Alliance LLC. - MarketBeat
Foundations Investment Advisors LLC Buys 3,292 Shares of Amgen Inc. $AMGN - MarketBeat
Geode Capital Management LLC Has $4.67 Billion Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock (US0311621009): Focus on earnings, pipeline, and US market exposure - AD HOC NEWS
Amgen Inc. stock (US0311621009): Weight-loss trial update keeps biotech giant in focus - AD HOC NEWS
Amgen Inc. stock (US0311621009): Investors weigh steady Q1 growth, Horizon deal integration and pipe - AD HOC NEWS
Amgen Presents 2nd Community Day as L.A. Builds Momentum for Kick Off of FIFA World Cup 2026 - Amgen
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? - The Motley Fool
Amgen stock (US0311621009): Shares edge up after latest trading update - AD HOC NEWS
Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy? - Yahoo Finance
Is It Too Late To Consider Amgen (AMGN) After Its Strong Multi Year Share Price Run? - simplywall.st
Is Trending Stock Amgen Inc. (AMGN) a Buy Now? - MSN
King Luther Capital Management Corp Increases Position in Amgen Inc. $AMGN - MarketBeat
Amgen Drug Gets New Warnings in Japan After Patient Deaths - WSJ
The Zacks Analyst Blog Highlights RTX, Wells Fargo, Amgen, Daily Journal and Tandy Leather - Zacks Investment Research
Amgen Named One of Newsweek’s Most Trustworthy Companies in America 2026 - Amgen
Top Stock Reports for RTX, Wells Fargo & Amgen - Yahoo Finance
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen's Growth Engine Is Just Getting Started (NASDAQ:AMGN) - Seeking Alpha
AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits? - TradingView
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
AMGN Fairly Valued by DCF at $292 - GuruFocus
Assessing Amgen (AMGN) Valuation After Japan Safety Concerns Over Rare Disease Drug - simplywall.st
Fisher Asset Management LLC Purchases 118,273 Shares of Amgen Inc. $AMGN - MarketBeat
Allstate Corp Has $13.13 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock (US0311621009): CFO retirement and earnings strength keep focus on guidance - AD HOC NEWS
Amgen Drug Reviewed Amid Deaths - Los Angeles Business Journal
Mita Ganatra Joins Amgen India as Executive Director, Finance - hrtoday.in
Amgen (AMGN) Announces Retirement of CFO Peter Griffith - Insider Monkey
Standing Bone Strong: Introducing a New Awareness Symbol for Osteoporosis - Amgen
Wealthquest Corp Acquires Shares of 3,374 Amgen Inc. $AMGN - MarketBeat
Legal & General Group Plc Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by New Age Alpha Advisors LLC - MarketBeat
Simplify Asset Management Inc. Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Stock Analysis: Strong ROE and Promising Outlook in the Healthcare Sector - DirectorsTalk Interviews
The Story of Maridebart Cafraglutide (MariTide) - Amgen
Amgen Inc. $AMGN Shares Sold by Swedbank AB - MarketBeat
Amgen Inc. $AMGN is Smead Capital Management Inc.'s 5th Largest Position - MarketBeat
Amgen stock (US0311621009): Shares edge lower after early-February trade update - AD HOC NEWS
Amgen stock (US0311621009): earnings beat and leadership change put biotech giant in focus - AD HOC NEWS
Does Amgen’s CFO Transition and Board Structure Shape a New Governance Story for AMGN? - simplywall.st
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):